Profile: Medicines Co (MDCO.O)
26 Jun 2017
The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
The Company's Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. In the United States, Angiomax is used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and for patients undergoing percutaneous Coronary Intervention (PCI), including patients with or at risk of heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS). In Europe, Angiomax is used as an anticoagulant in patients undergoing PCI, adult patients with acute coronary syndrome (ACS), and for the treatment of patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
The Company's IONSYS (fentanyl iontophoretic transdermal system) is a compact, needlefeee patient-controlled system for the short-term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Ionsys is used for short-term management of acute postoperative pain in hospitalized patients. It is marketed in the United States and the European Union.
The Company's Minocin IV is an intravenous formulation of a tetracycline-class antibiotic that is used for the treatment of infections due to susceptible strains of designated gram-negative bacteria, including those due to Acinetobacter spp, Escherichia coli, Enterobacter aerogenes, Shigella species, respiratory tract infections caused by Haemophilus influenza and respiratory tract and urinary tract infections caused by Klebsiella species. Minocin IV is also indicated for the treatment of infections caused by the microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug, including skin and skin structure infections caused by Staphylococcus aureus and upper respiratory tract infections caused by Streptococcus pneumoniae.
The Company's Orbactiv is an intravenous antibiotic that is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA), with a single dose treatment. Orbactiv is synthetically modified from a naturally occurring compound.
The Company competes with Eli Lilly, Johnson & Johnson/Centocor, Inc., Merck & Co., Inc., Iroko Pharmaceuticals, LLC, MediCure Inc., AcelRx, Inc., Teflaro, Vibativ and Allergan plc.
8 SYLVAN WAY
PARSIPPANY NJ 07054
Company Web Links
- BRIEF-Medicines Co says commenced implementation of workforce reduction
- BRIEF-Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor
- BRIEF-The Medicines Company Q1 loss per share $1.44
- BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran
- Federal appeals court rules Mylan can proceed with generic Angiomax